The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
I’m not sure that Ciz will focus on the NHS with just a LDT accreditation. Europe, inc the Uk have different validation requirements to the US.
That’s why they may need to licence it out to a bigger diagnostics company to put it on their platform, according to what AS says in one of his interviews. They would then go through the necessary steps to bring it to market.
He did state that they would work closely with the NHS and Cancer Uk as we move forward.
We’ve got our toe in 2 massive markets, US and China.
Remember, this whole company revolves around licensing out chunks of work to the experts in their field.
23mins in…
https://youtu.be/DDMQXK5wWUc?si=ho4lRexbwwiuLgBk
Your not kidding Dibs. £5.4mpa on wages alone last year. It’s probably gone up since then with the new hires.
Top heavy.
Correction, that’s today.
Yesterdays volume was 1.4m.
I’m seeing 424k traded.
What’s yours saying?
I’ve learned quite a lot over the last few days. I’m not experienced at investing in the medical field so I don’t want anybody to feel as if my questions have a negative slant. They’re just genuine, even if they appear basic or daft to others.
Luckily there are knowledgeable people on here that have patience with the likes of me.
VV
Thanks Brondby
I seem to recall AS in one of his Sunday Roast interviews suggesting that Europe and the UK would require a licensing deal with a big pharma producer to enable them to put out IP on their platform to attain CE and CA (UK) NICE and any other disparate accreditation’s. That of course was before our deal with Techne.
VV
Thanks Brondby and neilin for taking the time to respond. Both of you make sense.
It also covers another thought that I had after watching the webinar and reading the many comments on the OBD board regarding their lack of market uptake/penetration with a small in-house sales force.
There are also comments over there regarding pushback from doctors and influencers due to the lack of full trials data other than a LDT accreditation. Not sure how relevant that is given that the FDA take an overseeing role on LDTs as far as I can ascertain. Time will tell I guess.
Seems they’ve lost total confidence in management and looking at the details, I feel sorry for them.
So pleased AS has taken the licensing route and refuses to RNS fluff.
That said, an update or interview would be most welcomed.lol.
Thanks again.
VV
Source OBD webinar.
I would be interested in the views of the much more savvy in this field amongst you regarding the following proposed legislation changes and how this may affect any need for further more in depth trials in the future.
30 mins 30secs in…
https://youtu.be/bzUOeO-Om3g?si=QbloqAFkVbLtDQZ3
FDA presentation Oct 2023
https://www.fda.gov/media/173457/download?attachment#:~:text=The%20proposed%20rule%20is%20aimed,safety%20and%20effectiveness%20of%20LDTs.&text=The%20proposed%20rule%20seeks%20to,the%20IVD%20is%20a%20laboratory
Tia
VV
Our value to another business looking to BO Ciz depends on what profits they see from doing so.
OBD sell one of their tests ( can’t remember CIRT or PSE) for 1000usd @ 90pc margin. Their competitors (for a less accurate test) sell at between 500-750usd.
Anecdotely I’m convinced we are way off the mark in undervaluing ours using 100usd as a benchmark.
So the end price determines not only our revenues, but our worth to another business.
IMHO
VV
I too think that we could be bought out at some stage and I suspect you wouldn’t require binoculars to see the main suitor.
However, that’s not 100% guaranteed, and you can’t build a business on that objective alone, so Ciz need to put in place plans to survive and flourish on their own.
Before we’ve even validated the test, I would hope that AS has already been in discussions about the sales and marketing structures with our partners. We certainly don’t want to fall into the trap that OBD finds itself in. The less drag we have between validation and revenue realisation, the better.
Also let’s not forget when talking about a BO, there may need to be considerations for our current agreements. We haven’t seen the devil in the detail on these, so difficult to comment further.
VV
I’m not invested here but OBD has been on my watchlist since the positive newsflow last year.
I also wasn’t going to post on here but it appears somebody c&p’d my post from the Cizzle bb.
I’d start by saying I agree with the points that dibs has already outlined.
From a science and first mover point of view, excellent. But I find it somewhat conference league that they’ve only just hired a VP of sales.
That’s enough of a barrier to question if I should invest here but to compound that further, when Jon Burrows was asked what the sales targets are for the next 12 months, he didn’t know!!! He didn’t want to put a finger in the air in case he set the wrong expectations.
Considering they’ll be seeking additional funding from their “supportive” investors, he needs to get a handle on this point.
They’ll stay on the watchlist for now.
I’ve just watched their webinar.
They’re 6mths behind setting up a cohesive sales structure. They’ll need additional funding in the near term due to this and their less than satisfactory product uptake.
Thanks neilin, Brondby,
I guess I need to dial down my expectations for China. These expectations were based on Ciz delivering the immunoreagents to China by Q2 2022.
VV
It makes sense to a degree to carry out 1 trial at a time. There was a lot of expectation however that given the fact that iCCMAT/Intelliphecy we’re going to spend millions of dollars just to set up a subsidiary Company to run the test design/development/trials and distribution.
Just strange that it’s all gone quiet.
@XYZinvesting.
Breakout or buyout?
Yes to both.
I’ve just read that post again too. I also remember the interview when Alan stated he would report back on his China trip.
He wasn’t asked to do this, he offered it of his own accord, so I was slightly disappointed that we heard nothing.
It seems like radio silence regarding China since the announcement that the trials would be done in the US.
I know you’re all expecting a question from me 😀 so here it is…
If the trial over the pond is successful, I would imagine that China would have to get approval via. trials in order to roll it out over there, or is there a shortcut?
Also, why didn’t China opt to help develop the test in their country?
Having 2 trials running in parallel would have been the ideal scenario.
VV
“I think Ciz is on BO.”
Marvellous
That must be true then.😳
The upward rallies mostly seem to occur in the afternoon.
Yanks?
It doesn’t seem to hold any of its gains when it peaks.
I’d hazard that the sells from yesterday and today were the 10-20% traders.
It’s a rather difficult share to trade, given that the spread is normally a minimum of 10% and sometimes 15%, unless you have the time and patience to watch it.
The only way it’ll hold onto gains is if the Company give the market a reason to: i.e., the much awaited trial results.
Is ridiculous.
Nice fight back. I see our 750k seller is still here, but quickly swallowed up again.